Valneva to report nine-month 2026 financial results on November 24, 2026
The specialty vaccine company said it will hold a live webcast to discuss results and give a business update.
Valneva SE said on November 4, 2026 that it will report its nine-month 2026 financial results on November 24, 2026, as stated in the announcement title, with the company describing itself as a specialty vaccine company.1
The company said it will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update.1 The webcast will be accessible on the company's website and made available as an archive after the event concludes.1
In describing its business, Valneva said it develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.1 The company said it has advanced multiple vaccines from early research and development to approvals, and currently markets three proprietary travel vaccines.1
On pipeline progress, Valneva said its commercial revenues help fuel continued advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate under regulatory review, partnered with Pfizer, along with what the company called the world's most clinically advanced Shigella vaccine candidate, as well as other vaccine candidates targeting global public health threats.1
The release did not include specific cash position figures, trial enrollment updates, or regulatory decision timelines beyond the general pipeline description. The Form 6-K was signed by Thomas Lingelbach, Chief Executive Officer and President, dated November 6, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.